The knowledge of metabolic profile of synthetic cannabinoids is important for the detection of drugs in urinalysis due to the typical absence or low abundance of parent cannabinoids in human urine. The fungus Cunninghamella elegans has been reported to be a useful tool for metabolism study and thus applicability to synthetic cannabinoid metabolism was examined. In this study, 8-quinolinyl 1-(5-fluoropentyl)-1H-indole-3-carboxylate (5F-PB-22), 8-quinolinyl 1-pentyl-1H-indole-3-carboxylate (PB-22), [1-(5-fluoropentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone (XLR-11) and (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone (UR-144) were incubated with C. elegans and the metabolites were identified using liquid chromatographyquadrupole time-of-flight mass spectrometry. The obtained metabolites were compared with reported human metabolites to assess the suitability of the fungus to extrapolate human metabolism. 5F-PB-22 underwent dihydroxylation, dihydrodiol formation, oxidative defluorination, oxidative defluorination to carboxylic acid, ester hydrolysis and glucosidation, alone and/or in combination. The metabolites of PB-22 were generated by hydroxylation, dihydroxylation, trihydroxylation, dihydrodiol formation, ketone formation, carboxylation, ester hydrolysis and glucosidation, alone and/or in combination. XLR-11 was transformed through hydroxylation, dihydroxylation, aldehyde formation, carboxylation, oxidative defluorination, oxidative defluorination to carboxylic acid and glucosidation, alone and/or in combination. UR-144 was metabolised by hydroxylation, dihydroxylation, trihydroxylation, aldehyde formation, ketone formation, carboxylation, N-dealkylation and combinations. These findings were consistent with previously reported human metabolism except for the small extent of ester hydrolysis observed and the absence of glucuronidation. Despite the limitations, C. elegans demonstrated the capacity to produce a wide variety of metabolites including some major human metabolites of XLR-11 and UR-144 at high abundance, showing the potential for metabolism of newly emerging synthetic cannabinoids.
INTRODUCTION
New psychoactive substances have been increasingly appearing on the drug market. In particular, synthetic cannabinoids are the major class of drugs and over 160 compounds have been detected since 2008 with 24 of them appearing for the first time in 2015 [1] . Synthetic cannabinoids are cannabinoid type 1 (CB 1 ) and type 2 (CB 2 ) receptor agonists like Δ 9 -tetrahydrocannabinol, the active ingredient of cannabis, producing psychoactive effects but can be significantly more potent since cannabinoids and metabolites often have higher affinity and full agonist activity for both Electronic supplementary material The online version of this article (doi:10.1208/s12248-017-0078-4) contains supplementary material, which is available to authorized users. CB 1 and CB 2 receptors [2, 3] . As such, adverse health effects including seizures, psychosis, hallucinations, cardiotoxic effects, coma and deaths have been associated with the use of synthetic cannabinoids and it has become a serious public health concern [4] .
Due to the emergence of many synthetic cannabinoids within a short period, understanding of their pharmacology including metabolism is still limited. Knowledge of metabolites is important for forensic and clinical cases to prove the consumption of particular cannabinoids in urinalysis because synthetic cannabinoids are generally extensively metabolised and are usually not found without modification or found in low abundance in urine, requiring abundant and specific metabolites to be targeted instead [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] .
Different approaches have been taken for metabolite identification studies. While providing the most reliable data [15] , self-administration of drugs is difficult due to possible side effects and ethical concerns and therefore other approaches are commonly taken such as in vitro human hepatocytes [7] [8] [9] [16] [17] [18] [19] [20] and human liver microsomes (HLMs) [6, 14, [21] [22] [23] [24] [25] [26] and in vivo animals [5, [25] [26] [27] . The combination of controlled experiments such as human hepatocytes and authentic human urine analysis particularly appears to be valuable [28, 29] . However, cost, maintenance, species differences and/or ethics can be an issue with these models [30] . Furthermore, the quantity of metabolites obtained is usually not sufficient for isolation [30] , limiting the analysis to the use of mass spectrometry. However, unambiguous structural elucidation may not be possible without techniques such as nuclear magnetic resonance (NMR) spectroscopy [29] .
While less common, the potential of microbial models for metabolic studies have been investigated over the past few decades [30] . Cunninghamella elegans (C. elegans) is a fungus species known to metabolise many xenobiotics regio-and stereoselectively, similar to mammalian metabolism [30] . The fungus has enzymatic activity for both phase I and II enzymes [31] and possesses cytochrome P450 enzymes known as CYP509A1, which are close to the CYP51 family [32] . While little is known about the activity of CYP509A1, the fungus is capable of various reactions, such as hydroxylation, carboxylation, dihydrodiol formation, oxidative defluorination, N-dealkylation, glucosidation and sulfation [30, 33] , including those catalysed by human CYP1A2, CYP2C9, CYP2C19 and CYP2D6 [2, [33] [34] [35] [36] [37] . CYP3A4 is reported to be the major enzyme involved in the metabolism of [1-(5-fluoropentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone (XLR-11) and (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone (UR-144), two of the drugs investigated in this study, while CYP1A2 has a minor influence. There is no literature on specific enzymes responsible for the metabolism of 8-quinolinyl 1-(5-fluoropentyl)-1H-indole-3-carboxylate (5F-PB-22) and 8-quinolinyl 1-pentyl-1H-indole-3-carboxylate (PB-22), the other two drugs investigated. Some of the advantages of C. elegans include low cost, no ethical concern involved, simple and cheap maintenance of stock fungal cultures that can be subcultured, high reproducibility, diverse metabolic profile and larger amounts of metabolite produced, which might result in more fragment ions in mass spectrometric analysis, facilitating structural elucidation [30, 38] . More importantly, production of large amounts of metabolites has allowed for the structural characterisation of metabolites by NMR spectroscopy [39, 40] . Therefore, C. elegans may prove useful for synthetic cannabinoid metabolism study, especially where reference standards for metabolites of new compounds are not available.
The purpose of the study was to identify the metabolites of 5F-PB-22, PB-22, XLR-11 and UR-144 by C. elegans and to compare the fungal metabolites with human in vivo and in vitro metabolites reported in literature to examine whether C. elegans might have the possibility to be used as a complementary model for metabolism studies of synthetic cannabinoids with production of appropriate human metabolites. We have previously investigated the metabolism of synthetic cannabinoids JWH-018, JWH-073 and AM2201 by C. elegans, and their metabolic profiles were in good agreement with human metabolism, producing majority of the phase I human metabolites [33, 41] . The four synthetic cannabinoids were chosen because they have different structural classes from the cannabinoids in our previous study, and human in vivo and/or in vitro metabolism data are available. Metabolites were analysed by liquid chromatography-quadrupole time-offlight mass spectrometry (LC-QTOF-MS) with the aid of liquid chromatography-triple quadrupole (LC-QqQ) mass spectrometry. LC-QTOF-MS was mainly employed because it provides high-resolution mass spectrometric data, increasing the confidence of characterisation of metabolites by distinguishing isobaric compounds.
MATERIALS AND METHODS

Chemicals and Reagents
5F-PB-22 and PB-22 were obtained from PM separations (Capalaba, QLD, Australia), and XLR-11 and UR-144 were from the National Measurement Institute (North Ryde, NSW, Australia). Reagent grade dichloromethane, LC grade acetonitrile, acetone and sodium chloride were obtained from Chemsupply (Gilman, SA, Australia). LC-MS grade formic acid was obtained from Sigma-Aldrich (St. Louis, MO, USA). Glycerol and potassium dihydrogen orthophosphate were from Ajax Chemicals (Auburn, NSW, Australia). Potato dextrose agar, glucose, peptone and yeast extract were purchased from Oxoid Australia (Adelaide, SA, Australia).
Biotransformation by Fungus and Sample Preparation
C. elegans ATCC 10028b (Cryosite Ltd., South Granville, NSW, Australia) was cultured on potato dextrose agar plates at 27°C for 5 days ensuring the whole plates were covered with mycelia. The mycelia were then transferred to sterile physiological saline solution (1 plate of mycelia per 5 mL) and homogenised for 5 min. Approximately 1.5 mL aliquots of the homogenate were inoculated into 100 mL growth media, prepared according to the methods in [42] , in 250-mL Erlenmeyer flasks. The cultures were incubated for 48 h at 26°C and 180 rpm on an Infors HT Multitron rotary shaker (In vitro Technologies, Noble Park North, VIC, Australia). After 48 h, 0.5 mL of 5F-PB-22, PB-22, XLR-11 or UR-144 in acetone (2 mg/mL) was added to the culture and incubated for further 72 h. Two control samples were also incubated and consisted of (1) media and fungus without drugs to determine compounds unrelated to the drugs and (2) media and drug without fungus to determine degradation of the drugs.
After 72 h, fungus was removed by filtration using Buchner funnel and the remaining solution was extracted with dichloromethane (3 × 50 mL). The extracts were combined and evaporated to dryness using a Buchi rotary evaporator (In vitro Technologies, Noble Park North, VIC, Australia) followed by a vacuum pump. Each sample was reconstituted in 2 mL acetonitrile and was further diluted in acetonitrile by tenfold before injecting to LC-MS.
LC-QTOF Analysis
Chromatographic separation of samples was performed using an Agilent 1290 LC system with an Agilent Zorbax Eclipse XDBC18 analytical column (150 mm × 4.6 mm, 5 μm). Mobile phases were 0.1% formic acid in water (A) and 0.1% formic acid in acetonitrile (B) at a flow rate of 0.4 mL/ min. Due to the difference in polarity of the cannabinoids, two mobile phase gradients were used. For 5F-PB-22 and PB-22, 30% B was held until 1 min, ramped to 50% B at 3 min, 90% B at 20 min and held until 24 min, then ramped down to 30% B at 25 min and held for re-equilibration until 30 min. For XLR-11 and UR-144, 30% B was held until 1 min, ramped to 60% B at 3 min, to 90% B at 20 min and held until 24 min and ramped down to 30% B at 25 min for reequilibration until 30 min. Injection volume was 4 μL (MS mode) and 10 μL (targeted MS/MS mode).
Mass spectrometric data was acquired on an Agilent 6510 Accurate Mass Q-TOF Mass Spectrometer, equipped with an electrospray ionisation (ESI) source operated in positive ion mode. The following parameters were used: scanning mass range, m/z 100-1000 (MS) and m/z 100-950 (MS/MS); capillary voltage, 3500 V; nebulizer pressure, 30 psig; gas flow, 5 L/min; gas temperature, 325°C; fragmentor voltage, 160 V (XLR-11, UR-144) and 80 V (5F-PB-22, PB-22); collision energy, 10, 20 and 40 eV; skimmer voltage, 65 V. Mass calibration was performed over the m/z 50-3200 range with the mixture provided by the manufacturer. Automated real-time calibration during runs was in place using the following reference masses: m/z 121.0509 and m/z 922.0098.
Chromatographic and mass spectrometric data was analysed using Agilent MassHunter Workstation Software Qualitative Analysis (version B.06.00) for MS scan both manually looking at peaks present in fungus samples but absent in controls and with a PCDL library created by Agilent MassHunter PCDL Manager (version B.04.00) with known metabolites of the drugs to search for the potential metabolites. MS/MS scans were performed on the precursor ions which were suspected to be metabolites. Search parameters were as follows: mass tolerance, 20 ppm; maximum number of matches, 8; absolute peak area ≥5000. The criteria for metabolites were as follows: mass error of the protonated ion ≤5.1 ppm, consistent fragmentation pattern with proposed structure, reasonable retention time relative to other biotransformations, absence of the specific peak in controls.
LC-QqQ Analysis
An Agilent 6490 Triple Quadrupole mass spectrometer with ESI source (positive ion mode) coupled with an Agilent 1290 LC system was used for product ion scans for a few PB-22 metabolites (m/z 405 and 409) where some fragment ions for the potential metabolites were absent in QTOF analysis. Data derived from QqQ analysis is indicated in Supplementary Tables 2, 3 , and 4, respectively. Figure 1 shows MS/MS spectra as well as their structures with suggested fragmentation patterns of 5F-PB-22, PB-22, XLR-11 and UR-144 and their major metabolites.
5F-PB-22
Sixteen metabolites (labelled as F1-F16 in the order of retention time) were detected after incubation with C. elegans. They eluted between 6.4 and 12.6 min before the parent drug at 17.6 min (Fig. 2a) . The metabolites were generated by dihydrodiol formation (F10) followed by hydroxylation (F3), dihydroxylation (F7-F9), hydroxylation (F14-F16), oxidative defluorination to carboxylic acid (F13) followed by hydroxylation (F5, F6, F11), oxidative defluorination with dihydrodiol (F1), ester hydrolysis resulting in 5-fluoropentylindole-3-carboxylic acid (5F-PI-COOH, F12) followed by glucosidation (F2) or hydroxylation (F4). The mass errors of the metabolites based on the proposed biotransformations were all within 1.39 ppm. The top three abundant metabolites based on peak area were dihydrodiol (F10), hydroxylation (F15) and oxidative defluorination to carboxylic acid (F13). The proposed metabolic pathway of 5F-PB-22 is shown in Fig. 3 . Comparison of the fungal metabolites in this study with human hepatocytes and HLM metabolites in the literature is shown in Table I .
PB-22
A total of 30 metabolites (P1-P30) were found to elute between 6.2 and 15.1 min all before the parent drug at 21.7 min (Fig. 2b) . The following biotransformation was observed: carboxylation (P24) followed by hydroxylation (P12); dihydrodiol formation (P27) followed by hydroxylation (P3, P7) or ketone f ormation (P8, P14), dihydroxylation (P13, P15, P16, P19), hydroxylation (P26, P28), ketone formation (P29, P30) followed by hydroxylation (P17, P20-P23, P25) and glucosidation (P1) or dihydroxylation (P4, P5, P9, P18), trihydroxylation (P2), ester hydrolysis leading to pentylindole-3-carboxylic acid (PI-COOH) followed by hydroxylation (P6, P11) or glucosidation (P10). The mass errors of all the metabolites were 2.51 ppm or less. Three major fungal metabolites were dihydroxylation (P13), dihydrodiol formation with ketone formation (P8) and dihydroxylation (P16). The proposed metabolic pathway of PB-22 is shown in Fig. 4 . Comparison of the fungal metabolites in this study with human hepatocytes and HLM metabolites in the literature is shown in Table II .
XLR-11
Twenty six metabolites (X1-X26) were observed between 7.6 and 14.6 min with the parent drug eluting at 20.9 min (Fig. 2c) . XLR-11 was found to undergo aldehyde formation (X26), carboxylation (X22) followed by glucosidation (X14, X18) or hydroxylation (X10), hydroxylation (X21, X23), dihydroxylation (X3, X6, X9, X11-X13, X19, X20), oxidative defluorination (X25) followed by aldehyde formation (X16) or carboxylation (X8) or hydroxylation (X2, X7), oxidative defluorination to carboxylic acid (X24) followed by aldehyde formation (X15, X17) or carboxylation (X5) or hydroxylation (X1, X4). The mass errors of all the metabolites were within 5.10 ppm. The three most abundant metabolites were hydroxylation (X21), carboxylation (X22) and hydroxylation (X23). Proposed metabolic pathway of XLR-11 is shown in (Table III) .
UR-144
Twenty-five metabolites (U1-U25) were detected, eluting between 6.2 and 17.4 min before the parent drug at 26.1 min (Fig. 2d) . The biotransformation included aldehyde formation followed by hydroxylation (U19) or ketone formation (U21), carboxylation followed by hydroxylation (U6, U8, U10, U12, U15), dihydroxylation (U7, U11, U13, U16), hydroxylation (U22-U25), ketone formation followed by carboxylation (U17, U20) or hydroxylation (U14, U18), N-dealkylation followed by hydroxylation (U4, U9), trihydroxylation (U1-U3, U5). The mass errors of the proposed metabolites were all within 2.04 ppm. The top three abundant metabolites were dihydroxylation (U7), dihydroxylation (U11) and carboxylation with hydroxylation (U10). The proposed metabolic pathway of XLR-11 is shown in Fig. 6 . The observed fungal metabolites are compared with the metabolites in human urine and HLM reported in the literature (Table IV) . 
5F-PB-22
In MS/MS scan, 5F-PB-22 was fragmented to the ions at m/z 144 (an unchanged indole moiety) and 232 (an unaltered 5-fluoropentylindole moiety) and they were used as the basis for determining the structures of the metabolites (Fig. 1) . All three hydroxy metabolites (m/z 393, F14-F16) were found to be hydroxylated at the fluoropentyl side chain indicated by the fragment ions at m/z 144 representing an unchanged indole ring and at m/z 248 representative of a hydroxylated fluoropentylindole moiety. Two dihydroxy metabolites (m/z 409, F7, F8) showed fragment ions at m/z 144 and 248 indicating hydroxylation once at the fluoropentyl side chain and another at the quinoline moiety. F9 was another dihydroxy metabolite, hydroxylated twice at the fluoropentylindole moiety as shown by the fragment ion at m/z 264. But, the lack of fragment ions corresponding to the indole moiety limited further determination as to whether hydroxylation took place at the fluoropentyl side chain, the indole moiety or at both. A metabolite with dihydrodiol formation (m/z 411, F10) was characterised by the fragment ions at m/z 144 and 232 (Fig. 1), suggesting dihydrodiol formation at the quinoline moiety. Further hydroxylation of F10 led to the metabolite (m/z 427, F3) with a hydroxy group at the fluoropentylindole moiety as indicated by the fragment ion at m/z 248.
Oxidative defluorination to carboxylic acid (m/z 389, F13) was suggested by the fragment ions at m/z 144 (an unaltered indole ring) and 244 (a carboxylated pentylindole moiety). These fragments themselves only indicate that 5F-PB-22 was defluorinated and that the pentyl side chain has two additional oxygen atoms and two less hydrogen atoms. However, it is probably an N-pentanoic acid as it is reported to be a major metabolite of 5F-PB-22 in human hepatocytes in studies by Wohlfarth et al. [17] . Also, oxidative defluorination to carboxylic acid is a biotransformation previously observed for a synthetic cannabinoid AM2201 by C. elegans [33] . Further hydroxylation of F13 resulted in F5, F6 and F11 (m/z 405). F5 and F11 were hydroxylated at the quinoline moiety as the fragment ions at m/z 144 and 244 were still present. F6 was hydroxylated at the indole moiety, indicated by the fragment ions at m/z 160 (a hydroxylated indole ring) and 260 (a hydroxylated and carboxylated pentylindole). Although oxidative defluorination by itself was not observed, a metabolite with oxidative defluorination and dihydrodiol formation was indicated (m/z 409, F1). The only fragment ion detected was at m/z 230 suggesting a quinoline moiety with dihydrodiol formation and a pentylindole moiety with a hydroxy group. Despite the lack of the m/z 144 fragment ion, the position of the hydroxy group can be considered to be at the terminal carbon of the pentyl side chain since oxidative defluorination is a commonly reported pathway to simultaneously defluorinate and hydroxylate fluorinated synthetic cannabinoids [2, 6, 7, 16, 18, 19] and it has been reported for C. elegans [33] .
Ester hydrolysis led to the 5F-PI-COOH metabolite (m/z 250, F12) as indicated by the fragment ions at m/z 118 and 232 suggesting an unchanged indole moiety and unmodified 5-fluoropentylindole moiety, respectively. There was another unknown peak with m/z 250 in the extracted ion chromatogram, but careful examination of mass spectrum in full scan mode revealed the presence of a coeluting protonated ion at m/z 412, which has mass error of 1.39 ppm for a glucoside of F12. Thus, it seems to be a glucoside of 5F-PI-COOH with insource fragmentation (m/z 412, F2). In-source fragmentation of acyl glucuronides is reported for synthetic cannabinoid metabolites including 5F-PB-22 [16, 17] and is likely to occur with glucosides. A metabolite resulting from hydroxylation of F12 was shown by the fragment ions at m/z 248 indicating a 5-fluorohydroxypentylindole moiety and 134 corresponding to a hydroxyindole moiety (m/z 266, F4).
PB-22
PB-22 was fragmented similarly to 5F-PB-22 and resulted in two product ions at m/z 144 and 214 (Fig. 1) , corresponding to an unchanged indole ring and an unaltered pentylindole moiety. Both hydroxy metabolites (m/z 375, P26, P28) underwent hydroxylation at the pentyl side chain as shown by the fragment ions at m/z 144 and 230 with the latter indicating a hydroxylated pentylindole moiety. A dihydroxy metabolite (m/z 391, P13) showed the fragment ions at m/z 144 and 230 (Fig. 1) , indicating hydroxylation at both the pentyl side chain and the quinoline moiety while the other three dihydroxy metabolites (P15, P16, P19) were hydroxylated twice at the pentyl side chain as suggested by the fragment ions at m/z 144 and 246. A trihydroxylated metabolite (m/z 407, P2) was indicated to have two hydroxy groups at the pentyl side chain and another at the quinoline moiety (m/z 144, 246). A metabolite with dihydrodiol formation at the quinoline moiety (m/z 393, P27) was suggested by the ions at m/z 144 and 214 representing an unchanged pentylindole moiety. Hydroxylation of P27 at the pentyl side Metabolites with a ketone group at the pentyl side chain (m/z 373, P29, P30) were characterised by the fragment ions at m/z 144 and 228, the latter indicating a pentylindole moiety with a ketone group. Further hydroxylation occurred at the quinoline moiety for P17, P20, P22 and P25 (m/z 389) indicated by the fragment ions at m/z 144 and 228 and at the pentyl side chain for P21 and P23 suggested by the fragment ions at m/z 144 and 244. A glucoside of a hydroxylated metabolite with ketone was detected (m/z 551, P1), but it was not a glucoside of any of the phase I metabolites found as the position of the hydroxylation for this metabolite was at the indole moiety (m/z 160, 244). Four metabolites with a ketone group at the side chain and dihydroxylation (m/z 405, P4, P5, P9, P18) were formed. P4 has a hydroxy group each at the indole ring and the quinoline moiety (m/z 160, 244), P5 and P9 at the pentyl side chain and the quinoline moiety (m/z 144, 244) and P18 twice at the pentyl side chain (m/z 144, 260). For P9 and P18, the fragment ion at m/z 144 was absent but was confirmed by the LC-QqQ analysis. P24 (m/z 389) showed the fragment ions at m/z 144, 244, and based on the retention time and fragmentation pattern, it was considered to be identical to F13 and is proposed to be an N-pentanoic acid metabolite. Also, P12 (m/z 405) was determined to be identical to F5 and is proposed to be formed by hydroxylating P24 at the quinoline ring.
Similarly to 5F-PB-22, a glucoside of PI-COOH formed from ester hydrolysis (m/z 394, P10) was largely fragmented to m/z 232 by in-source fragmentation. Several fragment ions including m/z 118 and 214 suggested an unchanged pentylindole moiety. PI-COOH with hydroxylation at the pentyl side chain (m/z 248, P6, P11) was represented by the fragment ions at m/z 130 (an unaltered indole) and 230.
XLR-11
The structure of XLR-11 is similar to 5F-PB-22 with the quinoline moiety replaced by the tetramethylcyclopropyl (TMCP) ring. As such, the fragmentation pattern of XLR-11 was similar; m/z 144, 232 and additionally 125 (Fig. 1) , corresponding to the TMCP moiety, were observed. Hydroxylated metabolites (m/z 346, X21, X23) were found to have a hydroxy group at the TMCP ring as indicated by the fragment ions at m/z 144 and 232 (Fig. 1) . The absence of the fragment ion at m/z 125 also indicated the modification at the TMCP ring. There are three possible positions of hydroxylation: the alpha carbon to the carbonyl group; two methyl groups on the same side of the cyclopropyl ring as the hydrogen atom on the alpha carbon, which is an (E)-isomer, and two methyl groups on the other side of the ring from the hydrogen, a (Z)-isomer. Wohlfarth et al. reported, in their human hepatocyte studies, three hydroxy glucuronides with the two diastereomers eluting closely [16] . Thus, it is possible that the diastereomers might have coeluted under the chromatographic condition employed, resulting in two apparent peaks. Eight dihydroxy metabolites (m/z 362, X3, X6, X9, X11-X13, X19 and X20) were detected. X3, X9 and X11 were hydroxylated once each at the fluoropentyl side chain and at the TMCP ring (m/z 144, 248) and X6, X12, X13, X19 and X20 twice at the TMCP ring (m/z 144, 232). Aldehyde formation at the TMCP ring (m/z 344, X26) was characterised by the fragment ions at m/z 144 and 232. In fact, aldehydes are highly reactive and might undergo subsequent reaction before being detected. However, intermediate aldehyde metabolite of ebastine is reported to be isolated and characterised along with subsequent carboxylic acid metabolite after incubation with C. blakesleeana, another species of the genus Cunninghamella [50] , and therefore aldehyde is tentatively proposed in this study.
Three metabolites (m/z 360, X14, X18, X22) were observed with the fragment ions at m/z 144 and 232 corresponding to carboxylic acid at the TMCP ring. Similar to hydroxylation of the TMCP ring, there appears to be two possible positions for carboxylation at methyl carbons generating (E)-and (Z)-isomers. However, this does not explain the presence of three metabolites. Therefore, it is likely that one or two of the three metabolites are phase II metabolites with in-source fragmentation. As the retention time of X22 is relatively late compared to the other two, it is possible that X22 is a carboxy metabolite and X14 and X18 are glucosides of carboxy metabolites. The reason for only one chromatographic peak for the carboxy metabolite may be explained by coelution whereas the phase II metabolites may have sufficient difference in property to be separated by chromatography under the condition employed. Wohlfarth et al. also reported the presence of single carboxy metabolite, and it was the peak eluting last among the metabolites with m/z 360 and their glucuronides [16] . Alternatively, X14 or X18 may be hemiacetal formation as reported by Wohlfarth et al. [16] . would be the only case where the (E)-and (Z)-isomers are not coeluted. Therefore, it is possible that one of them is a metabolite that underwent dihydroxylation followed by internal dehydration as previously reported [16] .
UR-144
UR-144 is a defluorinated analogue of XLR-11. Hence, it showed the same fragment ions at m/z 125, 144 and the defluorinated ion at m/z 214, instead of 232 (Fig. 1) . Hydroxylation (m/z 328) of UR-144 occurred at the pentyl side chain with the fragment ions at m/z 125, 144 and 230 (U22, U23) and at the TMCP ring with the ions at 144 and 214 (U24, U25). U22 matched well in retention time with X25 (oxidative defluorination metabolite of XLR-11), suggesting 5-hydroxypentyl metabolite. The position of hydroxylation for U23 cannot be determined but is likely to be 4-hydroxypentyl metabolite since (ω)-OH and (ω-1)-OH metabolites of alkyl side chain have been reported for some synthetic cannabinoids [33, 51] . Further hydroxylation of hydroxy metabolites resulted in dihydroxylation (m/z 344, U7, U11, U13, U16) with one hydroxy group at the pentyl side chain and another at the TMCP ring as indicated by the fragment ions at m/z 144 and 230 (Fig. 1 ). U7 and U11 agreed well with X2 and X7, respectively, indicating that the hydroxy group at the side chain is likely to be at the terminal carbon. Trihydroxylated metabolites (m/z 360, U1-U3, U5) were then formed with a hydroxy group at the pentyl side chain and two at the TMCP ring as shown by the fragment ions at m/z 144 and 230. N-dealkylation of U24 and U25 resulted in despentyl hydroxy metabolites (m/z 258, U4, U9) with the fragment ion at m/z 144.
Aldehyde formation at the TMCP ring followed by hydroxylation at the pentyl side chain (m/z 342, U19) was suggested by the fragment ions at m/z 144 and 230. Due to the close retention time with X16 (oxidative defluorination metabolite of XLR-11), U19 is likely to be hydroxylated at the 5-position of the pentyl side chain. Aldehyde at the TMCP ring followed by ketone at the pentyl side chain (m/z 340, U21) showed the fragment ions at the m/z 144 and 228 representing ketone formation at the pentyl side chain. Carboxylation at the pentyl side chain with hydroxylation at the TMCP ring (m/z 358, U6, U8) was suggested by the ions at m/z 144 and 244 indicative of N-pentanoic acid, which was supported by the matching retention time with X1 and X4, respectively. Similarly, carboxylation at the TMCP ring with hydroxylation at the pentyl side chain (m/z 358, U10, U12, U15) was indicated by the ions at m/z 144 and 230. U10 was considered to be the same metabolite as X8 and is expected to have been hydroxylated at the terminal carbon.
Ketone formation at the pentyl side chain with hydroxylation at the TMCP ring (m/z 342, U14, U18) was suggested by the fragment ions at m/z 144 and 228. Ketone at the pentyl side chain with carboxylation at the TMCP ring (m/z 356, U17, U20) was represented by the fragment ions at m/z 144 and 228.
Comparison of Fungal Metabolites with Reported Human Metabolites
For 5F-PB-22 and PB-22, the fungal metabolites were generally in good agreement with reported human in vitro (Tables I and II) . Almost all types of individual biotransformations reported for the human metabolism were observed for the fungal metabolism though not necessarily in the same combinations; the only transformations that lacked with the fungus were cysteine conjugation and glucuronidation. The important difference, however, was that ester hydrolysis that forms 5F-PI-COOH/PI-COOH was the main pathway found by human hepatocytes [17] and HLM [22] while it was not a major pathway for C. elegans. In hepatocytes, three out of the five most abundant 5F-PB-22 metabolites are ester hydrolysis products with/without hydroxylation or glucuronidation whereas all seven major metabolites of PB-22 are ester hydrolysis products with/without hydroxylation, ketone formation and/or glucuronidation [17] . In contrast, all the fungal metabolites with ester hydrolysis were among the minor metabolites. However, it should be noted that metabolites generated by in vitro models like hepatocytes and HLM are not always consistent with human urinary metabolites. Accordingly, it would have been ideal to compare the fungal metabolites directly with human urinary metabolites; unfortunately, such data was unavailable. The majority of the human metabolites for XLR-11 and UR-144 were observed in the fungus samples (Tables III and IV) . For XLR-11, hemiacetal, N-dealkylation, dehydration, hemiketal, trihydroxylation and glucuronidation were the only individual transformations found in both in vivo and in vitro human metabolism that were not generated by the fungus. The major human urine metabolites have been reported to be oxidative defluorination and oxidative defluorination to carboxylic acid with/without hydroxylation [44, 45] , mostly of the pyrolysis product formed from thermal degradation due to smoking. All these metabolites were found in the fungus culture, though not of the pyrolysis product as the process of heating was not involved in this study, and metabolites with oxidative defluorination to carboxylic acid with hydroxylation (X1 and X4) were the fourth and fifth abundant fungal metabolites among 26 metabolites indicating good correlation in abundance. With UR-144, although metabolites with aldehyde, carboxylation, ketone or Ndealkylation alone were absent, all the reported individual human biotransformations including the four aforementioned were detected in fungal metabolism. Hydroxylation and dihydroxylation are reported major human urine metabolites [6, 48] and two dihydroxylated metabolites (U7 and U11) were found to be the two most abundant fungal metabolites.
These findings demonstrate that C. elegans is capable of most biotransformations observed for the four synthetic cannabinoids in humans, which is consistent with the previous studies on JWH-018, JWH-073 and AM2201 [33] . Hence, it shows the potential to be used to predict metabolism of future cannabinoids, complementary to other models, and to characterise metabolites by NMR analysis. However, two distinct differences between the fungus and human metabolism seem to exist. One is that glucuronides were not observed in this study and instead glucosides were generated by the fungus. This finding agrees with the study on the synthetic cannabinoid AM2201 that glucosidation and sulfation are the only phase II reactions observed for C. elegans metabolism while glucuronidation is the major phase II transformation in humans [33] . Similarly, for some other drugs, glucosidation and sulfation are reported to be the phase II reactions of C. elegans while the same drugs are glucuronidated and sulfated in humans [38, 52] . The latter experiments did not involve extraction step as a sample preparation, supporting that poor recovery of glucuronides in dichloromethane is not likely a reason for the absence of glucuronides in this study. Furthermore, the retention time of the glucosides observed in this study were between 6 and 10 min. The biotransformation proposed as 'dioxidation followed by internal dehydration' in the reference is included since it might be the same biotransformation If glucuronides of corresponding aglycones were present in the culture, they would likely have been extracted by dichloromethane, which did extract polar compounds derived from matrix eluting between 3 and 6 min. This indicates that phase II metabolites produced by the fungus, particularly glucosides, may be irrelevant and need to be interpreted with caution, if hydrolysis step is not included in sample preparation before urinalysis. The other difference is that ester hydrolysis was clearly not a favoured pathway in the fungal metabolism. Previously, incubation of steroidal drug, ethynodiol diacetate containing two ester groups, with C. elegans and Ocimum basilicum, has been reported [53] and while ester hydrolysis did not occur with C. elegans, three of the four metabolites by O. basilicum underwent hydrolysis suggesting that C. elegans may not favour ester hydrolysis in general. Some of the other discrepancy between the fungus and human metabolites may be due to dosages, possible co-administration of drugs in authentic human samples, incubation/sampling time. Finally, there are limitations of the comparison method. Each biotransformation observed for fungus and human metabolism was compared in this study. While this method provides useful information on the major metabolic pathways, specific isomers found in fungal metabolism may not always be the exact isomers found in human metabolism, e.g. 2-pentylhydroxy isomer in fungus vs. 4-pentylhydroxy isomer in human urine. This limitation is inherent to the mass spectrometry technique used and highlights the need to use other complimentary techniques such as NMR to aid unambiguous structural elucidation of metabolites and to facilitate more accurate comparison.
Comparison of Fungal Model with In Vitro Human Models
One of the incentives to use the fungus is the cost efficiency of the model. Unlike human hepatocytes or HLM, fungus can be repeatedly subcultured as required for new experiments.
Therefore, once the stock culture of the fungus is obtained, potato dextrose agar plates for subculturing will essentially be the only cost associated for the subsequent use of fungus.
Regarding extrapolation of metabolic profiles to human metabolism, human hepatocytes appear to best serve the purpose as the biotransformations observed are most closely aligned to human metabolites including the phase II metabolites as observed for XLR-11 (Table III) and the metabolite abundance is often closer to in vivo human metabolites [8] . While C. elegans did not match the human metabolites for XLR-11 as well as hepatocytes, it seems just as useful as HLM, generating most of the HLM metabolites in addition to those not produced by HLM (Tables I, II, III, and IV) .
As previously mentioned, the fungus metabolism can be scaled up to produce amounts of metabolites sufficient for NMR analysis. This is useful because it allows for more definitive characterisation of metabolites. Metabolites/isomers found in human urine and in vitro studies are not always conclusively characterised since commercially available reference standards do not cover all the potential metabolites and isomers. With upscaling of fungus metabolism followed by NMR analysis, the obtained metabolites could act as reference standards and in conjunction with human metabolism studies, appropriate biomarkers can be suggested. The quantity of drugs and volume of the media required for upscaling will depend on how much drug is metabolised, how many metabolites are to be analysed, abundance of major metabolites among all the metabolites, recovery of the metabolites in extraction and sensitivity of NMR spectrometer. In this study, these parameters were not quantified, and consequently, it is difficult to estimate the quantity and volume required. Previous studies report that as little as 0.9 mg of 18-nor-oxandrolone in 30 mL of media is sufficient for analysis of two metabolites [39] while five metabolites of adrenosterone were generated from 450 mg in 3 L, indicating the variability of the quantity and volume from case to case. The biotransformation proposed as 'dioxidation followed by internal dehydration' or 'dehydrated hydroxy' in the reference is included since they might be the same biotransformation
